Sanofi and BioNTech have entered into a multiyear exclusive collaboration and license agreement, which will leverage the scientific expertise of the two organisations to discover and develop up to five cancer immunotherapies.
The companies have agreed to $60 million in upfront and near-term milestone payments, payable to BioNTech under the terms of the agreement. Furthermore, BioNTech could receive over $300 million in development, regulatory and commercial milestones and other payments per product.
If commercialised successfully, BioNTech would also be eligible for tiered royalties on net sales up to double digits. In addition, BioNTech also has the option to co-develop and co-commercialise two of the five messenger RNA therapeutics products with Sanofi in the EU and US.
Complementing Sanofi’s global oncology footprint and scientific expertise, BioNTech will combine the use of its propriety mRNA technology platform with its extensive capabilities in developing immune-stimulating pharmaceuticals. As part of this effort, BioNTech will utilise its mRNA formulation technology, which enables targeted mRNA delivery in vivo, to generate novel cancer immunotherapies. It will also supply part of the mRNA material needed for development activities from its in-house GMP manufacturing unit.
“The collaboration with Sanofi is groundbreaking: through using our broad suite of mRNA technologies and extensive tumour immunology understanding, it will allow us to develop a completely new class of cancer immune-therapeutics with Sanofi, which we believe will have a profound and deep impact on the treatment of cancer,” says Ugur Sahin, CEO of BioNTech.